Merit Medical enrolls first patient in Motion study

Merit Medical Systems announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization or GAE, using Embosphere Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis.. MOTION, study. In 2022, the United States Food and Drug Administration FDA granted Merit’s Embosphere Microspheres “breakthrough device designation” for GAE. Under this designation, Embosphere Microspheres received priority review by the FDA, which allowed for accelerated review and development of the MOTION study protocol. “We look forward to the results of this study, as we feel it can offer another solution to the millions of people globally who suffer from arthritic knee pain every year,” said Craig J. McAsey, MD, Co-Global Principal Investigator of the MOTION study, and paid consultant of Merit. “In orthopedics, we are still searching for an effective alternative to surgery when possible; I am hopeful that this will actually bring us closer to that goal.”